Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.
about
Advances in the management of sepsis and the understanding of key immunologic defectsClinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.Prospective monitoring of cefepime in intensive care unit adult patientsAppraising contemporary strategies to combat multidrug resistant gram-negative bacterial infections--proceedings and data from the Gram-Negative Resistance Summit.Antimicrobial stewardship.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Pharmacodynamic profiling of antimicrobials against Gram-negative respiratory isolates from Canadian hospitalsAntibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignanciesExtended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Ceftaroline for complicated skin and skin-structure infections.Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind.Current concepts in the prevention and treatment of ventilator-associated pneumonia.Prolonged infusions of β-lactam antibiotics: implication for antimicrobial stewardship.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Evaluating outcomes of alternative dosing strategies for cefepime: a qualitative systematic review.Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-negative Bacteria in the Murine Thigh Infection Model.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival.Optimizing β-lactams treatment in critically-ill patients using pharmacokinetics/pharmacodynamics targets: are first conventional doses effective?A model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU.Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.Implementing extended-infusion cefepime as standard of care in a children's hospital: a prospective descriptive study.Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.Correlation of pharmacokinetic/pharmacodynamic-derived predictions of antibiotic efficacy with clinical outcomes in severely ill patients with Pseudomonas aeruginosa pneumonia.Population pharmacokinetics and dosing simulations of cefuroxime in critically ill patients: non-standard dosing approaches are required to achieve therapeutic exposures.Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients.Population pharmacokinetics of cefquinome in pigs.Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
P2860
Q26865386-F9FCC4D5-DE49-41C6-9556-BF14CFEFFCD7Q33676227-E0DE3DBE-AB3A-4461-AAA5-8983214F2348Q33919165-E2ECB85B-C518-4AB6-8C72-8564EC22102BQ34003193-5677D5AE-F662-4FAF-9C4E-3B6425E39B69Q34228050-9027AD76-6FF7-4986-A9B9-8D441B533F19Q34274190-6A8D6599-49EC-42FB-8DB2-9F9EA8035905Q35569189-8A37BD44-A07E-4732-AC68-7285C0951746Q35908084-026D46AD-DDEE-4258-A78D-963E15148B18Q35960873-48C588B0-005F-499B-A553-7736B85877EAQ36969880-2BECE58A-2D6A-4883-9CBF-37109DBF67BFQ37516599-34907415-AE23-4007-A3A3-D90B862B4326Q37643682-D38A0608-9567-4DFE-928E-4C2948871465Q37656243-EF554B4F-BFD0-433B-B84A-DCF0D329CA65Q37733561-F3D709AF-5BF2-4B07-B579-35EF10938C84Q37771799-5C7E784A-4215-4388-A6BC-BCBAFFE99714Q37867261-9D5456A8-C855-47B9-82F4-698987E8D3A4Q38073197-85720FD4-7E06-4E9C-BE88-9D37BB728E0CQ38100704-BF31698E-FB39-44FD-AAB5-E53592A1A721Q38138835-51D23985-94C9-4B46-AE7B-63F132CB266CQ38165138-6BB25043-980B-4F52-B379-643114B68C9EQ38313276-9563C9DA-472B-4187-9B55-D916D35179E4Q38605133-3E0419F8-B1F9-43FC-984C-AD601EBFAD7AQ38672016-BB4D1E5D-81B1-4122-A17E-CC2D8870460CQ38741453-C4E99B66-12A1-424D-AC94-A7AF4774C9A3Q39344408-3B665945-42B6-43D2-BD19-2703D40643BDQ39721085-8B150E48-EC7F-4AC7-8AFF-D41801C3F483Q40073466-8F8FFB93-C260-4FB5-814B-E2FA736E61F1Q40087256-740A2288-9DCA-4490-ACCC-10DF8C03AAFBQ40375664-77A22828-08F1-4194-93A8-BB47B26137A4Q41538340-52DA182D-44E8-45E7-95BE-575551373A4CQ41564878-A5E4A7C9-9A2C-40F1-B875-C2FDCE7D64C2Q42259839-60DDFE91-3359-4CDA-8C46-A025BD2B5CCCQ49064586-6384D90C-457A-431D-926B-00904CBD2610Q51014621-8D5E8DF1-CAAA-470F-93FB-FFE4FCBFABEBQ51295882-9F77E399-02B8-4CF8-90F7-9088DA6D4949Q55514103-6477E6C3-8AF9-4832-9E34-8859680F7DCDQ58701649-F612E61D-1ABD-4977-9E2A-D15BF08C15BA
P2860
Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Population pharmacokinetics of ...... ntilator-associated pneumonia.
@en
Population pharmacokinetics of ...... ntilator-associated pneumonia.
@nl
type
label
Population pharmacokinetics of ...... ntilator-associated pneumonia.
@en
Population pharmacokinetics of ...... ntilator-associated pneumonia.
@nl
prefLabel
Population pharmacokinetics of ...... ntilator-associated pneumonia.
@en
Population pharmacokinetics of ...... ntilator-associated pneumonia.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics of ...... ntilator-associated pneumonia.
@en
P2093
Anthony M Nicasio
David P Nicolau
Jared L Crandon
Joseph L Kuti
P2860
P304
P356
10.1128/AAC.01141-08
P407
P577
2009-02-02T00:00:00Z